Lysophosphatidic Acid is a Biomarker for Peritoneal Carcinomatosis of Gastric Cancer and Correlates with Poor Prognosis
Authors:
- 1 November 2017
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 21 (11) , 641-648
Abstract
Peritoneal carcinomatosis (PC) is an important cause of morbidity and mortality among patients with gastric cancer. Thus, it is important to identify an ideal biomarker for PC. Plasma and ascites samples were collected from gastric cancer patients with PC and a control group. Lysophosphatidic acid (LPA) levels were tested and analyzed. The plasma LPA levels of gastric cancer patients with PC were significantly higher than those in gastric cancer patients after radical resection (p = 0.046) and healthy volunteers (p < 0.001). Besides, plasma LPA levels were statistically lower after chemotherapy in gastric cancer patients with PC (p = 0.028). Furthermore, the ascites LPA levels were significantly higher in gastric cancer patients with peritoneal carcinomatosis than those in liver cirrhosis patients (p < 0.001). Moreover, ascites LPA levels were statistically lower after intraperitoneal chemotherapy injection than before (p < 0.001). In addition, the plasma LPA levels were significantly associated with serum CA125 levels (p = 0.032) and TNM stage in gastric cancer patients (p = 0.009). Individuals with plasma LPA levels >20,000 ng/mL had significantly worse overall survival (OS) than those with plasma LPA levels 24,000 ng/mL showed significantly worse progression-free survival (PFS) and OS (p < 0.001 in PFS and OS). This study demonstrated that LPA levels in plasma and ascites may be useful diagnostic biomarkers for PC of gastric cancer and that higher levels are associated with poor prognosis.Keywords
This publication has 64 references indexed in Scilit:
- Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2Oncology Letters, 2013
- The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancerInternational Journal of Oncology, 2012
- Lysophosphatidic Acid–Induced p21Waf1 Expression Mediates the Cytostatic Response of Breast and Ovarian Cancer Cells to TGFβMolecular Cancer Research, 2011
- Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal disseminationMolecular Cancer, 2011
- The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric CancerClinical Cancer Research, 2011
- IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancerOncogene, 2011
- Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic reviewBMC Gastroenterology, 2011
- Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1‐dependent upregulation of sphingosine kinase 1 transcriptionFEBS Letters, 2010
- Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancerJournal of Gynecologic Oncology, 2010
- NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancerBritish Journal of Cancer, 2008